151 related articles for article (PubMed ID: 19608331)
1. Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.
Kamijo Y; Ito C; Nomura M; Sai Y; Miyamoto K
Cancer Lett; 2010 Jan; 287(2):182-6. PubMed ID: 19608331
[TBL] [Abstract][Full Text] [Related]
2. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
Yokogawa K; Jin M; Furui N; Yamazaki M; Yoshihara H; Nomura M; Furukawa H; Ishizaki J; Fushida S; Miwa K; Miyamoto K
J Pharm Pharmacol; 2004 May; 56(5):629-34. PubMed ID: 15142340
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
Marchettini P; Stuart OA; Mohamed F; Yoo D; Sugarbaker PH
Cancer Chemother Pharmacol; 2002 Jun; 49(6):499-503. PubMed ID: 12107555
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice.
Shimada T; Nomura M; Yokogawa K; Endo Y; Sasaki T; Miyamoto K; Yonemura Y
J Pharm Pharmacol; 2005 Feb; 57(2):177-81. PubMed ID: 15720780
[TBL] [Abstract][Full Text] [Related]
5. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
[TBL] [Abstract][Full Text] [Related]
7. Determination of docetaxel and Paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies.
Zufía López L; Aldaz Pastor A; Aramendia Beitia JM; Arrobas Velilla J; Giraldez Deiró J
Ther Drug Monit; 2006 Apr; 28(2):199-205. PubMed ID: 16628131
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
[TBL] [Abstract][Full Text] [Related]
9. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20.
Weiszhár Z; Czúcz J; Révész C; Rosivall L; Szebeni J; Rozsnyay Z
Eur J Pharm Sci; 2012 Mar; 45(4):492-8. PubMed ID: 21963457
[TBL] [Abstract][Full Text] [Related]
10. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Gelderblom H; Verweij J; van Zomeren DM; Buijs D; Ouwens L; Nooter K; Stoter G; Sparreboom A
Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer.
de Bree E; Rosing H; Beijnen JH; Romanos J; Michalakis J; Georgoulias V; Tsiftsis DD
Anticancer Drugs; 2003 Feb; 14(2):103-10. PubMed ID: 12569296
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination].
Fushida S; Nao F; Kinami S; Ninomiya I; Fujimura T; Nishimura G; Ohta T; Yokogawa K; Miyamoto K; Miwa K
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1759-63. PubMed ID: 12402426
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of carbon nanoparticle-paclitaxel suspension for use in intraperitoneal chemotherapy.
Cai Y; Zhang X
Hepatogastroenterology; 2013; 60(128):1998-2003. PubMed ID: 24719940
[TBL] [Abstract][Full Text] [Related]
14. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
[TBL] [Abstract][Full Text] [Related]
15. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL.
Ellis AG; Webster LK
Cancer Chemother Pharmacol; 1999; 43(1):13-8. PubMed ID: 9923536
[TBL] [Abstract][Full Text] [Related]
17. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
Loos WJ; Baker SD; Verweij J; Boonstra JG; Sparreboom A
Clin Pharmacol Ther; 2003 Oct; 74(4):364-71. PubMed ID: 14534523
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions.
Mohamed F; Stuart OA; Sugarbaker PH
J Surg Res; 2003 Jul; 113(1):114-20. PubMed ID: 12943819
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]